AJMC® in the Press, August 2, 2024

An article from Managed Healthcare Executive^® referenced an article published on AJMC.com, the website of The American Journal of Managed Care^® (AJMC^®). The article, “Deuruxolitinib Demonstrates Efficacy, Tolerability in Patients With Moderate to Severe AA,” highlighted results from a poster presented at the 2024 American Academy of Dermatology Annual Meeting, which found that the Janus kinase inhibitor deuruxolitinib resulted in hair regrowth in patients with moderate to severe alopecia areata, with efficacy and tolerability.

An article from Pharmacy Times^® referenced a resource published by AJMC’s sister site, The Center for Biosimilars^®. The page, “The Center for Biosimilars: Biosimilars Approvals,” lists all 49 approved biosimilars in the US, including the name of each drug and the conditions it treats.